Maxim Group Downgrades Momenta Pharmaceuticals (MNTA) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
BofA/Merrill Lynch Still Likes Risk-Reward on Momenta Pharmaceuticals (MNTA)
January 22, 2015 7:01 AM ESTBofA/Merrill Lynch analyst Sumant Kulkami reiterated a Buy rating and $14 price target on Momenta Pharmaceuticals (NASDAQ: MNTA) saying they still like the risk-reward despite a court ruling in favor of Teva on Copaxone.
The analyst notes the ruling itself... More
Momenta Phama (MNTA) Reports Vacation of CAFC Decision on Copaxone Patents
January 21, 2015 8:33 AM ESTMomenta Phama (Nasdaq: MNTA) announced that the United States Supreme Court has vacated the 2013 decision of the Court of Appeals for the Federal Circuit ("CAFC") which found several of the Copaxone (20 mg injection) patents, including the one patent expiring September 1, 2015, invalid for being indefinite. The Supreme Court has overturned the long standing practice whereby the CAFC reviewed a District Court's claim interpretation "de novo," without deference to the... More
